Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 22, 2026

New Crypto: Pepeto Reveals Ecosystem Expansion And Bitcoin Price Eyes Recovery While Dogecoin Jumps on Elon Musk X Money News

View original at globenewswire.com
New Crypto: Pepeto Reveals Ecosystem Expansion And Bitcoin Price Eyes Recovery While Dogecoin Jumps on Elon Musk X Money News Dubai, UAE, March 22, 2026 (GLOBE NEWSWIRE) -- The Pepeto team just revealed a full ecosystem expansion covering the DeFi exchange, multi chain bridge, and token screening layer, with all three…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • When Elon Musk moves markets and the bitcoin price climbs, money always finds its way into early projects with the kind of ecosystem Pepeto is building

    60% confidence
  • The platform could bring crypto to 600 million X users

    60% confidence
  • X Money opens to the public in April

    60% confidence
  • X Money is being called a once in a generation product that will include crypto tools, high interest savings, investing features, and payment rails inside a platform with 600 million users

    60% confidence
  • Whispers are growing that Pepeto could launch on X Money at the same time the Binance listing goes live

    60% confidence
  • The Pepeto ecosystem now covers three products moving forward at the same time. The DeFi exchange runs zero fee trading on Ethereum. The multi chain bridge moves tokens between Ethereum, BNB Chain, and Solana at zero cost with instant completion. And AI screening checks every smart contract before it shows up on the platform. Together they make a full trading ecosystem, not a one trick project hoping to add more later

    60% confidence

Data points we hold from this source

SpaceX · bitcoin holdings8000 BTC
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com